Sarah B. Goldberg on New Immunotherapy Options for Patients With Lung Cancer

Video

Sarah B. Goldberg, MD, MPH, assistant professor of medicine at Yale Cancer Center, discusses new treatment options for patients with non-small cell lung cancer (NSCLC).

Sarah B. Goldberg, MD, MPH, assistant professor of medicine at Yale Cancer Center, discusses new treatment options for patients with non-small cell lung cancer (NSCLC).

The FDA has approved two immunotherapy agents for NSCLC, nivolumab (Opdivo) and pembrolizumab (Keytruda) as an option for patients who already received one line of chemotherapy that did not work. These two agents work by blocking the PD-1 pathway, which lets the patient's immune system attack the cancer.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.